Study of BMS-833923 in Two Specific Patients With Basal Cell Nevus Syndrome

• Status: Completed
• Trial end date: 2017-05-01
• Target enrollment: 0
• Participant gender: Female

Summary

This is an extension study of Protocol CA194002 to allow 2 specific participants with basal cell nevus syndrome in the CA194002 study at Princess Margaret Cancer Centre who are still benefitting from the study drug BMS-833923 to continue receiving the study drug. This study will continue to evaluate the safety and tolerability of BMS-833923 in these participants.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Health Network, Toronto

Criteria

Inclusion Criteria:

• Signed consent

• Two specific study participants enrolled on protocol CA194002 at Princess Margaret Cancer Centre and remain on BMS-833923 at the time of study entry

• Women, age 18 years and above

• Agree to use methods to prevent pregnancy, not pregnant or breastfeeding

Exclusion Criteria:

• Known symptomatic brain metastasis

• A serious uncontrolled medical disorder or active infection, which would impair the ability of the patient to receive protocol therapy

• Gastrointestinal disease or surgery that could impact the absorption of study drug

• Inability to swallow oral medication

• Inability to be venipunctured and/or tolerate venous access

• Uncontrolled or significant cardiovascular

• Any other medical, psychiatric and/or social reason

• Have HIV, HepB, or HepC

• Exposure to immunosuppressants and immunotherapy concurrently with study treatment and up to 3 months

• Acceptable physical and laboratory test findings

• History of allergy to compounds chemically-related